An Autologous Therapeutic Dendritic Cell Vaccine Transfected with Total Lung Carcinoma RNA Stimulates Cytotoxic T Lymphocyte Responses Against Non-Small Cell Lung Cancer

REFERENCES

• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998; 392: 245–52
   PubMed Web of Science ®Google Scholar
• Bercovici N, Haicheur N, Massicard S, et al. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. J Immunother. 2008; 31(1)101–12
   PubMed Web of Science ®Google Scholar
• Avigan DE, Vasir B, George DJ, et al. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother. 2007; 30(7)749–61
   PubMed Web of Science ®Google Scholar
• Hildenbrand B, Sauer B, Kalis O, et al. Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells–a pilot study. Prostate. 2007; 67(5)500–8
   PubMedGoogle Scholar
• O'Mahony D, Kummar S, Gutierrez ME, et al. Non-small-cell lung cancer vaccine therapy: a concise review. J Clin Oncol. 2005; 23(35)9022–8
   PubMedGoogle Scholar
• Tuyaerts Sandra, Aerts Joeri L., Corthals Jurgen. Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother. 2007; 56(10)1513–37
   PubMed Web of Science ®Google Scholar
• Zeng G, Li Y, El-Gamil M, et al. Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res. 2002; 62: 3630–3635
   PubMed Web of Science ®Google Scholar
• Tacken PJ, Torensma R, Figdor CG. Targeting antigens to dendritic cells in vivo. Immunobiology. 2006; 211: 599–608
   PubMed Web of Science ®Google Scholar
• Brichard VG, Lejeune D. Cancer immunotherapy targeting tumor-specific antigens: towards a new therapy for minimal residual disease. Expert Opin Biol Ther. 2008; 8(7)951–68
   PubMed Web of Science ®Google Scholar
• Ikeda H, Lethe B, Lehmann F, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity. 1997; 6(2)199–208
   PubMed Web of Science ®Google Scholar
• Slingluff CL, Jr, Colella TA, Thompson L, et al. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens. Cancer Immunol Immunother. 2000; 48(12)661–72
   PubMed Web of Science ®Google Scholar
• Kerkmann-Tucek A, Banat GA, Cochlovius B, et al. Antigen loss variants of a murine renal cell carcinoma: implications for tumor vaccination. Int J Cancer. 1998; 77(1)114–22
   PubMedGoogle Scholar
• Moore MW, Carbone FR, Bevan MJ. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell. 1988; 54(6)777–85
   PubMed Web of Science ®Google Scholar
• Paglia P, Chiodoni C, Rodolfo M, et al. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med. 1996; 183(1)317–22
   PubMed Web of Science ®Google Scholar
• Ignatius R, Mahnke K, Rivera M, et al. Presentation of proteins encapsulated in sterically stabilized liposomes by dendritic cells initiates CD8(+) T-cell responses in vivo. Blood. 2000; 96(10)3505–13
   PubMedGoogle Scholar
• Zhao X, Wei YQ, Peng ZL. Induction of T cell responses against autologous ovarian tumors with whole tumor cell lysate-pulsed dendritic cells. Immunol Invest. 2001; 30(1)33–45
   PubMed Web of Science ®Google Scholar
• Geiger J, Hutchinson R, Hohenkirk L, et al. Treatment of solid tumors in children with tumor-lysate-pulsed dendritic cells. Lancet. 2000; 356: 1163–5
   PubMed Web of Science ®Google Scholar
• Hatfield P, Merrick AE, West E, et al. Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy. J Immunother. 2008; 31(7)620–32
   PubMedGoogle Scholar
• Sawabata N, Hirano H, Inoue M, et al. Immunohistochemical analysis of resected clinical stage I pulmonary adenocarcinomas with high preoperative levels of serum carcinoembryonic antigen. Ann Thorac Surg. 2003; 76(1)203–207
   PubMedGoogle Scholar
• Wang K, Wu YL, Zhou Q, et al. Large-scale Generation of Mature Clinical Grade Dendritic Cells. Cancer Res Prevention Treatment. 2004; 31(8)458–460
   Google Scholar
• Kalady MF, Onaitis MW, Padilla KM, et al. Enhanced dendritic cell antigen presentation in RNA-based immunotherapy. J Surg Res. 2002; 105(1)17–24
   PubMedGoogle Scholar
• Mitchell DA, Nair SK. RNA-transfected dendritic cells in cancer immunotherapy. J Clin Invest. 2000; 106(9)1065–1069
   PubMed Web of Science ®Google Scholar
• Bergant M, Meden L, Repnik U, et al. Preparation of native and amplified tumour RNA for dendritic cell transfection and generation of in vitro anti-tumour CTL responses. Immunobiology. 2006; 211: 179–189
   PubMedGoogle Scholar
• de Vries IJ, Lesterhuis WJ, Scharenborg NM, et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res. 2003; 9(14)5091–100
   PubMed Web of Science ®Google Scholar
• McIlroy D, Gregoire M. Optimizing dendritic cell-based anti-cancer immunotherapy: maturation state does have clinical impact. Cancer Immunol Immunother. 2003; 52: 583–91
   PubMed Web of Science ®Google Scholar
• Jarnjak-Jankovic S, Saebøe-Larssen S, Kvalheim G, et al. mRNA transfection of DC in the immature or mature state: comparable in vitro priming of Th and cytotoxic T lymphocytes against DC electroporated with tumor cell line-derived mRNA. Cytotherapy. 2007; 9(6)587–92
   PubMed Web of Science ®Google Scholar
• Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science. 1990; 247: 1465–1468
   PubMed Web of Science ®Google Scholar
• Nair SK, Boczkowski D, Morse M, et al. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol. 1998; 16(4)364–369
   PubMed Web of Science ®Google Scholar
• Van Tendeloo VF, Ponsaerts P, Lardon F, et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood. 2001; 98(1)49–56
   PubMed Web of Science ®Google Scholar
• Lu D, Benjamin R, Kim M, et al. Optimization of methods to achieve mRNA-mediated transfection of tumor cells in vitro and in vivo employing cationic liposome vectors. Cancer Gene Ther. 1994; 1(4)245–252
   PubMed Web of Science ®Google Scholar
• Okano K, Fukui M, Suehiro Y, et al. Evaluation of an mRNA lipofection procedure for human dendritic cells and induction of cytotoxic T lymphocytes against enhanced green fluorescence protein. Tumor Biol. 2003; 24(6)317–24
   PubMedGoogle Scholar
• Ponsaerts P, Van Tendeloo VF, Cools N, et al. mRNA-electroporated mature dendritic cells retain transgene expression, phonotypical properties and stimulatory capacity after cryopreservation. Leukemia 2002; 16(7)1324–1330
   PubMedGoogle Scholar
• Ponsaerts P, Van den Bosch G, Cools N, et al. Messenger RNA electroporation of human monocytes, followed by rapid in vitro differentiation, leads to highly stimulatory antigen-loaded mature dendritic cells. J Immunol. 2002; 169(4)1669–1675
   PubMed Web of Science ®Google Scholar
• Grünebach F, Müller MR, Brossart P. RNA transfection of dendritic cells. Methods Mol Med. 2005; 109: 47–54
   PubMedGoogle Scholar
• Michiels A, Tuyaerts S, Bonehill A, et al. Delivery of tumor-antigen-encoding mRNA into dendritic cells for vaccination. Methods Mol Biol. 2008; 423: 155–63
   PubMedGoogle Scholar